The global bioanalytical testing services market size reached USD 3.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 7.4 Billion by 2033, exhibiting a growth rate (CAGR) of 8.54% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 3.4 Billion |
Market Forecast in 2033
|
USD 7.4 Billion |
Market Growth Rate 2025-2033 | 8.54% |
Bioanalytical testing services are used for the quantitative determination of drugs concentration and their metabolites and pharmacodynamic biomarkers in biological fluids. These services include method validation for ensuring results that demonstrate accuracy, precision, selectivity, and stability and assure the accuracy of sample analysis results. Nowadays, they rely on developed and validated methods for detecting analytes and metabolites in a diversity of complex biological matrices. Some of these matrices are urine, serum, blood, saliva, plasma, breast milk, cell lysates, cell culture media, tissue homogenates, cerebrospinal fluid (CSF), and wastewater from pharmaceutical production.
The increasing occurrence of chronic health conditions worldwide on account of sedentary lifestyles and increasing consumption of fast food, along with the rising preferences for personalized medical treatments, represents one of the key factors influencing the market positively. Additionally, biopharmaceutical companies are using bioanalytical testing services for validation of assays and drug development at both preclinical and clinical stages. Moreover, the global transmission of the coronavirus disease (COVID-19) and the lack of effective vaccines and treatments are driving the need for widespread screening and early detection. This has increased the usage of bioanalytical testing services for point-of-care (POC) diagnostic and controlling the spread and minimizing the resultant health and societal impact of the infection. Apart from this, several companies are incorporating a wide range of innovative techniques to offer rapid high-volume analyses. These techniques generally include mass spectrometry, immunochemistry, Ultra-Performance Liquid Chromatography (UPLC), automated sample preparation using robotics or turbulent flow, and large sample storage combined with bar code systems. This, in confluence with the improving healthcare infrastructure, is strengthening the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global bioanalytical testing services market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on molecule type, test type and workflow.
Breakup by Molecule Type:
Breakup by Test Type:
Breakup by Workflow:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Almac Group, Charles River Laboratories International Inc., Frontage Laboratories Inc., ICON plc, Intertek Group plc, Laboratory Corporation of America Holdings, Pace Analytical Services LLC, PPD Inc., PRA Health Sciences, SGS SA, Syneos Health and Toxikon Corporation.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Molecule Type, Test Type, Workflow, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Almac Group, Charles River Laboratories International Inc., Frontage Laboratories Inc., ICON plc, Intertek Group plc, Laboratory Corporation of America Holdings, Pace Analytical Services LLC, PPD Inc., PRA Health Sciences, SGS SA, Syneos Health, Toxikon Corporation |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global bioanalytical testing services market was valued at USD 3.4 Billion in 2024.
We expect the global bioanalytical testing services market to exhibit a CAGR of 8.54% during 2025-2033.
The sudden outbreak of the COVID-19 has led to the rising adoption of bioanalytical testing services for drug discovery and clinical trials for novel vaccines against the coronavirus infection, thereby positively influencing the market growth.
The increasing prevalence of various chronic health conditions, along with the growing application of bioanalytical testing services for validation of assays and drug development, at both preclinical and clinical stages, is primarily driving the global bioanalytical testing services market.
Based on the molecule type, the global bioanalytical testing services market can be categorized into small molecule and large molecule. Currently, small molecule accounts for the majority of the global market share.
Based on the test type, the global bioanalytical testing services market has been segregated into ADME, PK, PD, bioavailability, bioequivalence, and others. Among these, bioavailability currently holds the largest market share.
Based on the workflow, the global bioanalytical testing services market can be bifurcated into sample preparation, sample analysis, and others. Currently, sample analysis exhibits a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global bioanalytical testing services market include Almac Group, Charles River Laboratories International Inc., Frontage Laboratories Inc., ICON plc, Intertek Group plc, Laboratory Corporation of America Holdings, Pace Analytical Services LLC, PPD Inc., PRA Health Sciences, SGS SA, Syneos Health, and Toxikon Corporation.